LULU BLOOD BATH: Buying the Knife at $100.61
THE LULU MASSACRE
$LULU just got hit by a wrecking ball. -17.38% in a single session is retail carnage. The street is panicking over revenue misses and soft guidance, but panic is where I find my liquidity. When everyone is dumping the bags, the smart money is sniffing out the oversold bounce.
| Metric | Value |
|---|---|
| Current Price | $100.61 |
| 1-Day Change | -17.38% |
| Option Strategy | 2026-10-02 $105 Calls |
| Entry Zone | $2.25 - $2.78 |
| Target Exit | $3.63 - $4.44 |
| Upside Potential | 52% |
THE CATALYST: REVENUE DECAY
The market hates uncertainty. Management lowered the forecast, signaling the 'athleisure' bubble has finally popped. Revenue growth is stalling and inventory bloat is looming. The 'So What?' is simple: $LULU is now trading at a valuation that assumes complete irrelevance. This is an overreaction. Massive institutional selling creates a vacuum. Shorts are currently overextended. Any positive technical setup will trigger a forced covering rally. Compare this to the volatility seen in $NKE or $UA during their cyclical downturns; the bottom happens fast.
THE PLAY: OCT 02 $105 CALLS
We are looking at 27 days to expiration. Theta decay is currently our enemy, but the IV crush from this dump makes premium dirt cheap. I am entering the $105 strike zone. I want to catch the mean reversion. We aren't looking for a structural recovery of the brand; we are looking for a swing trade off the support floor. If this rips to $108 by Tuesday, we are banking the profit and rotating into $TSLA or high-beta biotech setups like $MRNA for the next squeeze.
Keep eyes on the dark pool prints. Large buyers love picking up these shards of glass after a blowout. Don't marry the stock. Trade the volatility. If it breaks below $98, cut the position and move on. No sentiment, just math.
Data Source: https://fxcapta.com/stockinfo/
Disclaimer: Eachi Alpha provides independent financial analysis based on algorithmic market data. This content is for informational and educational purposes only and does not constitute financial, investment, or trading advice. Trading securities involves significant risk. Eachi Alpha is not responsible for any financial losses or damages resulting from the use of this information. Always perform your own due diligence before making investment decisions.